Hepatitis C News

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Monica Konerman, MD, director of the Michigan Medicine NAFLD Clinic, discusses results of a study that found opioid use to be twice as common among patients with chronic liver disease compared with other common chronic diseases.

The use of response-guided therapy, or RGT, reduces effective treatment times by up to 50% in patients with hepatitis C virus infection and could significantly cut costs for expensive direct-acting antiviral therapy, according to research presented at the Liver Meeting 2018 in San Francisco.

SAN FRANCISCO — Preemptive administration of pangenotypic direct-acting antiviral therapy resulted in rapid viral suppression of hepatitis C in patients without HCV who received a heart transplantation with an HCV-positive organ, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Mavyret yielded nearly perfect SVR rates after 8 weeks of therapy in compensated cirrhosis with HCV, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — NS5A resistance-associated substitutions at several positions, including Y93, may hold information about DAA treatment response, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — U.S. states in the Appalachian region demonstrated increased rates of hepatitis B among women despite overall national rates of acute and chronic HBV remaining stable or declining among women and children, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Individuals with hepatitis C who underwent DAA therapy experienced significant reductions in both hepatocellular carcinoma and decompensation risk compared with untreated patients, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Despite continued drug use, hepatitis C reinfection rarely occurred in a cohort of patients with HCV who received opioid agonist therapy and were treated for HCV, according to findings presented at The Liver Meeting 2018.

SAN FRANCISCO — Universal screening of pregnant women at risk for hepatitis C was more efficient and cost-effective compared with risk-based screening, according to data presented at The Liver Meeting 2018.